274 related articles for article (PubMed ID: 10477909)
1. Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer.
Drachenberg DE; Elgamal AA; Rowbotham R; Peterson M; Murphy GP
Prostate; 1999 Oct; 41(2):127-33. PubMed ID: 10477909
[TBL] [Abstract][Full Text] [Related]
2. Cytokine variations in patients with hormone treated prostate cancer.
Wise GJ; Marella VK; Talluri G; Shirazian D
J Urol; 2000 Sep; 164(3 Pt 1):722-5. PubMed ID: 10953133
[TBL] [Abstract][Full Text] [Related]
3. Comparison of serum prostate specific membrane antigen, prostate specific antigen, and free prostate specific antigen levels in radical prostatectomy patients.
Douglas TH; Morgan TO; McLeod DG; Moul JW; Murphy GP; Barren R; Sesterhenn IA; Mostofi FK
Cancer; 1997 Jul; 80(1):107-14. PubMed ID: 9210715
[TBL] [Abstract][Full Text] [Related]
4. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
5. Prostate health index and prostate cancer gene 3 score but not percent-free Prostate Specific Antigen have a predictive role in differentiating histological prostatitis from PCa and other nonneoplastic lesions (BPH and HG-PIN) at repeat biopsy.
De Luca S; Passera R; Fiori C; Bollito E; Cappia S; Mario Scarpa R; Sottile A; Franco Randone D; Porpiglia F
Urol Oncol; 2015 Oct; 33(10):424.e17-23. PubMed ID: 26162485
[TBL] [Abstract][Full Text] [Related]
6. Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma.
Adler HL; McCurdy MA; Kattan MW; Timme TL; Scardino PT; Thompson TC
J Urol; 1999 Jan; 161(1):182-7. PubMed ID: 10037394
[TBL] [Abstract][Full Text] [Related]
7. Comparison between clinical significance of serum proinflammatory protein interleukin-6 and classic tumor markers total PSA, free PSA and free/total PSA prior to prostate biopsy.
Milicević N; Mrcela M; Lukić I; Mandić S; Horvat V; Galić J
Coll Antropol; 2014 Mar; 38(1):147-50. PubMed ID: 24851609
[TBL] [Abstract][Full Text] [Related]
8. Comparison of prostate cancer gene 3 score, prostate health index and percentage free prostate-specific antigen for differentiating histological inflammation from prostate cancer and other non-neoplastic alterations of the prostate at initial biopsy.
De Luca S; Passera R; Bollito E; Manfredi M; Scarpa RM; Sottile A; Randone DF; Porpiglia F
Anticancer Res; 2014 Dec; 34(12):7159-65. PubMed ID: 25503144
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic and prognostic significance of prostate specific antigen and serum interleukin 18 and 10 in patients with locally advanced prostate cancer: a prospective study.
Dwivedi S; Goel A; Natu SM; Mandhani A; Khattri S; Pant KK
Asian Pac J Cancer Prev; 2011; 12(7):1843-8. PubMed ID: 22126577
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of the nadir prostate specific antigen level after hormone therapy for prostate cancer.
Kwak C; Jeong SJ; Park MS; Lee E; Lee SE
J Urol; 2002 Sep; 168(3):995-1000. PubMed ID: 12187207
[TBL] [Abstract][Full Text] [Related]
11. Prostate-specific antigen levels and clinical response to flutamide as the second hormone therapy for hormone-refractory prostate carcinoma.
Fujikawa K; Matsui Y; Fukuzawa S; Takeuchi H
Eur Urol; 2000 Feb; 37(2):218-22. PubMed ID: 10705202
[TBL] [Abstract][Full Text] [Related]
12. The effect of high grade prostatic intraepithelial neoplasia on serum total and percentage of free prostate specific antigen levels.
Ramos CG; Carvahal GF; Mager DE; Haberer B; Catalona WJ
J Urol; 1999 Nov; 162(5):1587-90. PubMed ID: 10524873
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy.
Sridhara R; Eisenberger MA; Sinibaldi VJ; Reyno LM; Egorin MJ
J Clin Oncol; 1995 Dec; 13(12):2944-53. PubMed ID: 8523059
[TBL] [Abstract][Full Text] [Related]
14. Percent free PSA as an additional measure in a prostate cancer screen.
Miele ME
Clin Lab Sci; 2001; 14(2):102-7. PubMed ID: 15625982
[TBL] [Abstract][Full Text] [Related]
15. Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer.
Thalmann GN; Sikes RA; Chang SM; Johnston DA; von Eschenbach AC; Chung LW
J Natl Cancer Inst; 1996 Jun; 88(12):794-801. PubMed ID: 8637045
[TBL] [Abstract][Full Text] [Related]
16. Elevated serum chromogranin A precedes prostate-specific antigen elevation and predicts failure of androgen deprivation therapy in patients with advanced prostate cancer.
Chuang CK; Wu TL; Tsao KC; Liao SK
J Formos Med Assoc; 2003 Jul; 102(7):480-5. PubMed ID: 14517586
[TBL] [Abstract][Full Text] [Related]
17. Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml.
Haese A; Graefen M; Steuber T; Becker C; Pettersson K; Piironen T; Noldus J; Huland H; Lilja H
Prostate; 2001 Oct; 49(2):101-9. PubMed ID: 11582588
[TBL] [Abstract][Full Text] [Related]
18. Predictive value of total and percent free prostate specific antigen in high grade prostatic intraepithelial neoplasia lesions: results of the Tyrol Prostate Specific Antigen Screening Project.
Horninger W; Volgger H; Rogatsch H; Strohmeyer D; Steiner H; Hobisch A; Klocker H; Bartsch G
J Urol; 2001 Apr; 165(4):1143-5. PubMed ID: 11257656
[TBL] [Abstract][Full Text] [Related]
19. High serum prostate-specific antigen levels in the absence of prostate cancer in Middle-Eastern men: the clinician's dilemma.
Kehinde EO; Sheikh M; Mojimoniyi OA; Francis I; Anim JT; Nkansa-Dwamena D; Al-Awadi KA
BJU Int; 2003 May; 91(7):618-22. PubMed ID: 12699471
[TBL] [Abstract][Full Text] [Related]
20. Locally advanced prostate cancer--biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy.
Bruchovsky N; Klotz L; Crook J; Goldenberg SL
Cancer; 2007 Mar; 109(5):858-67. PubMed ID: 17265527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
